ANEW MEDICAL, INC., a biopharmaceutical technology company focused on developing therapies for central nervous system and neurodegenerative diseases, has completed a business combination with Redwood Acquisition Corp., a special purpose acquisition company. The combined entity will continue under the ANEW MEDICAL, INC. name and is set to trade on the Nasdaq Global Market under new ticker symbols WENA and WENAW for shares and warrants, respectively. Dr. Joseph Sinkule, CEO of ANEW, expressed excitement about the company’s future in developing and commercializing three major platform technologies after accessing the Nasdaq market. Advisors for the deal included Chardan, Cyruli Shanks & Zizmor, LLP, Hunter Taubman Fischer & Li LLC, and Loeb & Loeb LLP.

Biotechnology, Healthcare, Mergers and Acquisitions,United States